449 Shares in argenx SE (NASDAQ:ARGX) Purchased by Captrust Financial Advisors

Captrust Financial Advisors purchased a new position in shares of argenx SE (NASDAQ:ARGX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 449 shares of the company’s stock, valued at approximately $243,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ARGX. Blue Trust Inc. boosted its stake in argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the last quarter. Cromwell Holdings LLC boosted its stake in argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its stake in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in argenx in the second quarter valued at about $76,000. Finally, Keudell Morrison Wealth Management purchased a new position in argenx in the third quarter valued at about $207,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $515.00 to $650.00 in a research note on Friday, November 1st. Baird R W cut shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Truist Financial boosted their price target on shares of argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Finally, JMP Securities boosted their price target on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average target price of $635.11.

argenx Price Performance

ARGX stock opened at $607.21 on Monday. argenx SE has a one year low of $327.73 and a one year high of $630.00. The stock has a market cap of $36.66 billion, a PE ratio of -690.01 and a beta of 0.59. The firm has a 50 day simple moving average of $581.03 and a two-hundred day simple moving average of $515.48.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the previous year, the company earned ($1.25) EPS. On average, research analysts expect that argenx SE will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.